Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician

Peter J Angell,¹ Neil Chester,¹ Nick Sculthorpe,² Greg Whyte,¹ Keith George,¹ John Somauroo¹,³

ABSTRACT
The use of performance-enhancing and social drugs by athletes raises a number of ethical and health concerns. The World Anti-Doping Agency was constituted to address both of these issues as well as publishing a list of, and testing for, banned substances in athletes. Despite continuing methodological developments to detect drug use and associated punishments for positive dope tests, there are still many athletes who choose to use performance and image enhancing drugs. Of primary concern to this review are the health consequences of drug use by athletes. For such a large topic we must put in place delimitations. Specifically, we will address current knowledge, controversies and emerging evidence in relation to cardiovascular (CV) health of athletes taking drugs. Further, we delimit our discussion to the CV consequences of anabolic steroids and stimulant (including amphetamines and cocaine) use. These drugs are reported in the majority of adverse findings in athlete drug screenings and thus are more likely to be relevant to the healthcare professionals responsible for the well-being of athletes. In detailing CV health issues related to anabolic steroid and stimulant abuse by athletes we critique current research evidence, present exemplar case studies and suggest important avenues for ongoing research. Specifically we prompt the need for awareness of clinical staff when assessing the potential CV consequences of drug use in athletes.

INTRODUCTION
In a bid to improve performance and/or aid recovery, various pharmaceutical products have been used, both openly (legally) and in a clandestine manner against the rules of governing bodies, by a broad array of athletes.¹ The World Anti-Doping Agency (WADA) strictly regulates the use of pharmaceutical products in competitive sport. WADA produced and regularly updates the World Anti-Doping Code that includes a prohibited drug list. This list dictates what is and is not acceptable, and serves as a deterrent against the use of performance and image enhancing drugs. Of primary concern to this review are the health consequences of drug use by athletes. For such a large topic we must put in place delimitations. Specifically, we will address current knowledge, controversies and emerging evidence in relation to cardiovascular (CV) health of athletes taking drugs. Further, we delimit our discussion to the CV consequences of anabolic steroids and stimulant use (including amphetamines and cocaine) use. These drugs are reported in the majority of adverse findings in athlete drug screenings and thus are more likely to be relevant to the healthcare professionals responsible for the well-being of athletes. In detailing CV health issues related to anabolic steroid and stimulant abuse by athletes we critique current research evidence, present exemplar case studies and suggest important avenues for on-going research. Specifically we prompt the need for awareness of clinical staff when assessing the potential CV consequences of drug use in athletes.

ANABOLIC AGENTS
There are a number of drugs that are used in an attempt to improve performance and/or aid recovery, various pharmaceutical products have been used, both openly (legally) and in a clandestine manner against the rules of governing bodies, by a broad array of athletes.¹ The World Anti-Doping Agency (WADA) strictly regulates the use of pharmaceutical products in competitive sport. WADA produced and regularly updates the World Anti-Doping Code that includes a prohibited drug list. This list dictates what is and is not acceptable, and serves as a deterrent against the use of performance and image enhancing drugs. Of primary concern to this review are the health consequences of drug use by athletes. For such a large topic we must put in place delimitations. Specifically, we will address current knowledge, controversies and emerging evidence in relation to cardiovascular (CV) health of athletes taking drugs. Further, we delimit our discussion to the CV consequences of anabolic steroids and stimulant use (including amphetamines and cocaine) use. These drugs are reported in the majority of adverse findings in athlete drug screenings and thus are more likely to be relevant to the healthcare professionals responsible for the well-being of athletes. In detailing CV health issues related to anabolic steroid and stimulant abuse by athletes we critique current research evidence, present exemplar case studies and suggest important avenues for on-going research. Specifically we prompt the need for awareness of clinical staff when assessing the potential CV consequences of drug use in athletes.

Table 1 WADA prohibited substance list (Adapted from WADA 2012 Prohibited List²)

<table>
<thead>
<tr>
<th>Prohibited substance group</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anabolic agents</td>
<td>Anabolic androgenic steroids</td>
</tr>
<tr>
<td></td>
<td>Other anabolic agents; for example, clenbuterol</td>
</tr>
<tr>
<td>Peptide hormones, Growth factors and related substances</td>
<td>Erythropoietin</td>
</tr>
<tr>
<td>β-2 Agonists</td>
<td>Human chorionic gonadotrophin</td>
</tr>
<tr>
<td></td>
<td>Insulins and insulin-like growth factors</td>
</tr>
<tr>
<td>Hormone and metabolic modulators</td>
<td>All except therapeutic doses of salbutamol, formoterol and salmeterol</td>
</tr>
<tr>
<td>Diuretics and masking agents</td>
<td>Aromatase inhibitors</td>
</tr>
<tr>
<td>Stimulants</td>
<td>Amphetamine</td>
</tr>
<tr>
<td></td>
<td>Dextran</td>
</tr>
<tr>
<td></td>
<td>Cocaine</td>
</tr>
<tr>
<td></td>
<td>Methamphetamine</td>
</tr>
</tbody>
</table>

WADA, World Anti-Doping Agency.
testosterone (T) and the various analogues that are based around testosterone, usually referred to as androgenic anabolic steroids (AS). In addition to AS there are non-steroid agents that are used in an attempt to generate the same anabolic effects. These include the β-2 agonist, clenbuterol (which is additionally used as an anorectic agent to reduce body fat), human growth hormone (HGH) and insulin/insulin-like growth factors. Other growth factors are commonly used in between courses of anabolic agent use and these include human chorionic gonadotropin (HCG) and erythropoietin (EPO) and more recently selective androgen receptor modulators. Whatever the classification, the purpose of anabolic and growth factors is to stimulate skeletal muscle growth and promote rapid recovery following intensive training. From a clinical perspective it is also worth noting that EPO is predominantly used to boost endurance exercise performance and in general has not crossed over to amateur and recreational sports performers. AS, HGH, HCG and insulin/insulin-like growth factors, however, are routinely used by professional, amateur and recreational athletes. Consequently, the likelihood of clinicians coming across users of these particular drugs is much greater.

It is worthy to note that the classification of AS covers a number of structural variants. Classically, AS are classified as water-soluble orally active forms (17α-alkylated) and lipid-soluble parenteral forms (17β-esterified). In addition, they are often also classified as either testosterone-based, dihydrotestosterone-based (DHT) or 19-nortestosterone-based (Nandrolone) all of which have differing properties and expected side effects. The situation is further complicated by belief among users, often stemming from anecdotal advice, that some AS are better for predominantly ‘bulking’ (eg. Deca-Durabolin) while others are better suited to losing body fat or ‘cutting’ (eg. Winstrol). Users will often use these different forms of AS in varying quantities. The use of AS is also characterised by periods of use followed by periods of abstinence, or ‘cycles’. This helps to maximise the effects of the drugs while also limiting the negative consequences and allowing the body to normalise following an ‘on’ cycle. Furthermore, users will often supplement their cycles with additional pharmaceutical agents both when bulking (eg. Insulin, human growth hormone) and when losing body fat (clenbuterol, cytome, 2,4, dinitrophenol). Finally, there are a surprising number of drugs used to attempt to limit side effects of AS use or normalise the hypothalamo-pituitary-gonadal (HPG) axis following an AS cycle. These include estrogen receptor antagonists (tamoxifen), selective estrogen receptor inhibitors (clomifene), aromatase inhibitors (arimidex), 5α-reductase inhibitors (finasteride) and HPG axis stimulators such as HCG.

Evidence of athlete use of AS has been available since the 1950s with AS contributing to c. 60% of adverse findings according to recent WADA reports. In the general population there are data showing an increase in the prevalence of AS use. Despite such widespread use there is still some controversy as to the CV health consequences of taking AS. Large sample epidemiological evidence of the CV health consequences of long-term AS use is lacking, likely because of the reluctance to admit use and/or possession. In addition, evidence for a link between AS use and CV disease outcomes or end-points is mostly limited to case study reports. Published case studies include AS use associated with myocardial infarction, stroke, embolism and other CV health issues (table 2). Although caution should be expressed in implying cause and effect from case studies, they can provide direction for case series and experimental studies as well as informing/educating clinical practitioners.

Significant research attention has focused on the impact of AS use on CV disease risk factors namely blood pressure, lipid profile, left ventricular (LV) mass, cardiac function and arterial function. Elevated systemic arterial blood pressure is associated with an increased CV disease risk. Compared to healthy controls, AS users have increased resting and exercise systolic blood pressure. Conversely, other studies have not observed increased blood pressure in AS user. Differences in the training level of the participants along with age could be responsible for the differences seen in these studies.

AS have also been associated with negative alterations in lipid profiles. Changes reported include a decrease in high-density lipoprotein (HDL), an elevation in low-density lipoprotein (LDL) and reduced apolipoprotein levels, possibly through up-regulation of hepatic triglyceride lipase. The changes in lipid profiles indicate an increase in atherosclerotic risk. Increases in homocysteine, a naturally occurring amino-acid thought to have a role in vaso-control, and C-reactive proteins (CRP), an acute-phase protein that rises in response to inflammation, have been implicated as risk factors for CV disease. Grace and Davies demonstrated a significant increase in CRP in AS users. While demonstrated a significant increase in CRP in AS users. While Zmuda et al. observed no significant increases in homocysteine in a group of AS users, Graham et al. noted a significant elevation in homocysteine in AS users as well as those who had abstained from AS use for 3 months, indicating a possible effect of AS on vitamin B absorption. Previous studies have also suggested a possible link between AS use and thrombotic risk through alterations in haemoglobin levels.

An increase in LV mass is an independent risk factor for CV disease. AS use has been associated with an increase in LV mass but there is conflicting data. There are some data in AS users that suggest a reduction in systolic cardiac function although this is not a consistent finding between studies. A reduction in diastolic function has been observed more frequently and it has been suggested that a reduction in myocardial relaxation/elastance is associated with AS use. AS use has also been associated with reduced endothelial function in conduit arteries and Sader et al. noted a reduced flow-mediated dilation in AS users as well as a reduced vasodilator response to glyceryl-trinitrate.

There is a growing evidence base that AS use can have a negative effect on multiple CV disease risk factors. We present

**Table 2** Cardiovascular events and risk factors from AS use

<table>
<thead>
<tr>
<th>Event/risk factor</th>
<th>Case study</th>
<th>Cohort study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Sudden death</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Thromboembolism</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Cardiac hypertrophy</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Cardiomyopathy</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Endocarditis</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Heart failure</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Subdural haematoma</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Elevated blood pressure</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Decreased HDL</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>C-Reactive protein</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

AS, anabolic steroids; HDL, high-density lipoprotein.
Case study 1
A 25-year-old bodybuilder who was enrolled into a research study gave a detailed history of prolonged AS use. He self-reported no cardiac health problems. The participant was 1.95 m and 127 kg with an LV mass of 218 g on cardiac MRI. While absolute LV mass was high this was normalised when indexed for fat free mass. Left ventricular (LV) ejection fraction was normal (63%), while right ventricular (RV) ejection fraction was slightly reduced at 49%. LV diastolic function, measured using ultrasound echocardiography, was moderately depressed (significant increases in late atrial filling and tissue velocities). Heart rate was 75 beats per min and the ECG was unremarkable. Blood pressure was 131/71 mm/Hg. Total cholesterol was within normal clinical limits (4.6 mmol/l), but high-density lipoproteins were significantly reduced in the participant at 0.46 mmol/l. Low-density lipoproteins were above clinically acceptable levels at 3.77 mmol/l. The participant had an elevated level of alanine transaminase indicative of reduction in liver function. In addition, both testosterone and sex-hormone binding globulin were well below those expected within a male, at 2.13 and 6 nmol/l, respectively. Gamma glutamyltransferase was not assessed. Based on changes to numerous CV risk factors, this athlete was informed of the test outcomes and was directed to seek a general practitioner consultation.

While recent data have started to paint a clearer picture of some of the negative CV consequences of AS use, longitudinal data are still lacking making the long-term chronic effects of AS use difficult to ascertain.3 There is also uncertainty in relation to the impact of withdrawal of AS use on CV risk factors. Inherently, the study of AS use is complicated by many factors. Specifically, most studies recruit diverse cohorts of self-selected AS users. In these groups there is likely great heterogeneity in total AS dose, poly-drug regimens employed as well the difficulty in verifying the ‘true’ dosages used.

There is little direction given to clinicians and health practitioners regarding the identification of clandestine AS use. One of the reasons for athletes engaging in illicit AS use is that there are few ‘tell tale’ signs particularly in those sports where elevated strength and/or fat free mass is relatively commonplace. AS use occurs predominantly but not exclusively in strength and/or power athletes. Of the nine adverse findings for AS use by the UK Anti-Doping Agency, three were from professional rugby players.41 It is worth noting that clinicians are far more likely to encounter recreational athletes using AS, training for predominantly aesthetic purposes. AS users may have rapid increases in lean mass, excessive hypertrophy of the trapezius, the shoulder musculature42 and a large neck circumference43 increases in lean mass, excessive hypertrophy of the trapezius, which occurs in approximately 50% of users (including acne fulminans and acne conglobata).44 Consequently, clinicians may be suspicious of AS use in muscular individuals with acne (and/or scarring from previous eruptions) extending beyond the face to the back, chest and upper arms.44 Another common side effect of AS use is the development of female breast tissue (gynaecomastia) because of the aromatisation of AS to estrogen. The size and rate of development will vary depending on the type and duration of AS exposure with cases ranging from small areas of puffy tissue behind the nipple to easily recognisable breast tissue. It must be stressed however that these are general signs that may indicate AS use, but clinicians should be wary of unfairly targeting individuals who are simply prone to acne, or have a genetic basis for a muscular shoulder girdle.
amphetamines and the repercussions may include myocardial infarction, aortic dissection and sudden cardiac death.57

Little has been done by way of measuring both the acute/chronic effects of stimulant use/abuse on a range of CV risk factors. While significant CV events are associated with their use, the extent to which these contribute to atherosclerotic disease compared with other known CV risk factors is worthy of further examination. With regard to amphetamines, emphasis has largely focused on the adverse effects relating to the CNS; however, it is clear that their effects can be wide-ranging and no less significant.

**STIMULANTS—COCAINE AND OTHERS**

Cocaine is one of the most frequently used recreational drugs worldwide. The prevalence of use in the UK has been steadily increasing over recent years with 6.6% of 16–24 year olds admitting to regular use and figures suggesting over 1 million current cocaine users in the UK.58 Despite limited use as a performance-enhancing drug, there is still a relatively high level of adverse findings for cocaine use in athletes. According to WADA around 11.3% of adverse findings for stimulants were as a result of cocaine use.4 Athletes are not immune to the lure of social drugs like cocaine.

The use of cocaine has been associated with acute and chronic cardiovascular disease.59 60 Cocaine inhibits norepinephrine reuptake in the sympathetic system leading to overstimulation60 and may cause release of catecholamines from central and peripheral stores.61 Acute coronary syndromes (including myocardial ischemia and infarction) are the commonest cardiac events secondary to cocaine abuse.50 61 This may be due to coronary artery spasm, increase in myocardial oxygen consumption from increases in heart rate and blood pressure, and a prothrombotic state.62 63 Most myocardial infarctions occur in the absence of atherosclerotic coronary disease and are unrelated to the dose and frequency of cocaine use.64 Cocaine abuse may however also lead to premature coronary disease sometimes with quite rapid onset.65 Cocaine abuse may also lead to coronary artery aneurysms, aortic dissection, rupture, vasculitis and stroke.66–68

Arrhythmias are not common with cocaine use, but sinus tachycardia, sinus bradycardia, supraventricular, ventricular arrhythmias and bundle branch blocks have been reported.59 69 70 A dilated cardiomyopathy can be caused by cocaine use and a cocaine-induced myocarditis has been reported at postmortem in 20–50% of cases.71 Myocarditic changes, however, may be reversible if identified early and abstention from further cocaine abuse occurs. In the case study detailed the ECG changes with a significant cardiac event are shown in a young professional athlete who has a cocaine abuse history.

**Case study 2**

We briefly describe the case of a 27-year-old professional skater with a history of cocaine abuse. He developed retrosternal chest pain and ECG changes of inferolateral ST elevation (figure 1) after taking cocaine. His symptoms settled with nitrates and he developed T-wave inversion on his ECG the following day (figure 2) with a rise in T roponin I of 18.5 mg/l. He had normal left ventricular systolic function on echocardiography. On cardiac catheterisation he had a smooth 40% stenosis in the ostial left anterior descending artery with the other coronary branches normal (figure 3). He was initially treated with anti-platelets, heparin and a β-blocker, but as it was felt that he had sustained a myocardial infarction due to coronary artery spasm, the β-blocker was substituted with a calcium channel blocker prior to discharge from hospital. He remained pain-free when further reviewed at 3 months.

While detection of cocaine use, unless openly admitted, can be problematic for the practitioner there are certain psychological and physiological indications that may help inform the healthcare provider. Cocaine use can produce euphoria, decreased appetite and need for sleep, but may also cause anxiety, irritability, paranoia and hallucinations. There may be associated tachycardia, sweating, pupil dilatation and nausea. Withdrawal after chronic use mainly causes psychological symptoms including depression, anxiety and increased sleep.

Other common stimulants used by athletes include caffeine and nicotine (from smoking tobacco, chewing tobacco and smoking cessation products). Both caffeine and nicotine have

Figure 1  ECG 1: inferolateral ST elevation with chest pain. This figure is only reproduced in colour in the online version.
been shown to have cardiac effects. Caffeine is used by athletes as a stimulant to decrease the feelings of fatigue and elevate heart rate and neural activity. The effect of caffeine will increase myocardial O2 and has been shown to increase blood pressure as well as raise the level of free-fatty acids in the blood, thereby increasing blood viscosity. If used in moderate doses there are minimal long-term side effects to caffeine use; however, extremely high doses have been associated with cardiac arrhythmias and events in otherwise healthy individuals. Cigarette smoking has long been known to promote atherosclerosis, with an increased risk of sudden death, myocardial infarction and stroke. The use of nicotine therapies such as transdermal patches, inhalators and gum as well as the common use of chewing tobacco in some sports has also been associated with an increased cardiovascular event risk. Again, much of these data have come from case study and anecdotal data, with larger studies not observing a significant increase in risk of cardiovascular events. Like most other stimulants further research is required and given that both caffeine and nicotine are not completely banned admission and monitoring of use may be easier than with other drugs.

**SUMMARY**
This review has attempted to describe available data and exemplar case studies detailing the potential CV health issues surrounding the use of some of the most common drugs detected in doping screens on athletes. Negative CV health effects do occur but more controlled research trials are required alongside longitudinal studies of chronic drug use. Available data demonstrate enough concern in relation to CV health and drug use that healthcare practitioners should be fully educated to help detect signs and symptoms and support athlete treatment and recovery where appropriate.
REFERENCES


10. Applebaum-Bowden D, Haffner SM, Hazzard WR. The dyslipoproteinaemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein cholesterol. Metabolism 1987;36:949.


